肠道菌群
失调
干细胞
干细胞疗法
医学
粪便细菌疗法
生物信息学
免疫学
生物
抗生素
重症监护医学
微生物学
艰难梭菌
遗传学
作者
Lamiaa A. Ahmed,Khaled F. Al- Massri
出处
期刊:Current Molecular Pharmacology
[Bentham Science]
日期:2023-02-01
卷期号:16 (1): 43-59
被引量:2
标识
DOI:10.2174/1874467215666220222105004
摘要
Dysbiosis has been linked to various diseases ranging from cardiovascular, neurologic, gastrointestinal, respiratory, and metabolic illnesses to cancer. Restoring of gut microbiota balance represents an outstanding clinical target for the management of various multidrug-resistant diseases. Preservation of gut microbial diversity and composition could also improve stem cell therapy which now has diverse clinical applications in the field of regenerative medicine. Gut microbiota modulation and stem cell therapy may be considered a highly promising field that could add up towards the improvement of different diseases, increasing the outcome and efficacy of each other through mutual interplay or interaction between both therapies. Importantly, more investigations are required to reveal the cross-talk between microbiota modulation and stem cell therapy to pave the way for the development of new therapies with enhanced therapeutic outcomes. This review provides an overview of dysbiosis in various diseases and their management. It also discusses microbiota modulation via antibiotics, probiotics, prebiotics, and fecal microbiota transplant to introduce the concept of dysbiosis correction for the management of various diseases. Furthermore, we demonstrate the beneficial interactions between microbiota modulation and stem cell therapy as a way for the development of new therapies in addition to limitations and future challenges regarding the applications of these therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI